Compare OGN & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | PRGS |
|---|---|---|
| Founded | 1923 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 1995 |
| Metric | OGN | PRGS |
|---|---|---|
| Price | $13.43 | $29.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $11.40 | ★ $49.50 |
| AVG Volume (30 Days) | ★ 2.6M | 600.4K |
| Earning Date | 05-07-2026 | 03-30-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 7.79 |
| EPS | ★ 0.55 | 0.53 |
| Revenue | ★ $6,216,000,000.00 | $397,572,000.00 |
| Revenue This Year | $0.45 | $3.70 |
| Revenue Next Year | $1.67 | $1.08 |
| P/E Ratio | ★ $24.42 | $56.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.69 | $23.82 |
| 52 Week High | $13.49 | $65.50 |
| Indicator | OGN | PRGS |
|---|---|---|
| Relative Strength Index (RSI) | 72.03 | 44.62 |
| Support Level | $10.05 | $26.18 |
| Resistance Level | $13.46 | $30.05 |
| Average True Range (ATR) | 0.05 | 1.43 |
| MACD | -0.11 | -0.28 |
| Stochastic Oscillator | 57.14 | 9.95 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.